Roche walks away from Re­pare sol­id tu­mor deal just weeks af­ter $40M mile­stone pay­out

Roche has ter­mi­nat­ed its li­cense agree­ment with Re­pare Ther­a­peu­tics for the can­cer drug ca­mon­sert­ib in a move de­scribed by an­a­lysts as “par­tic­u­lar­ly strange” in light of a re­cent mile­stone pay­ment.

The phar­ma gi­ant de­cid­ed to end the agree­ment ef­fec­tive May 7 af­ter re­view­ing its pipeline and “evolv­ing ex­ter­nal fac­tors,” ac­cord­ing to a Re­pare re­lease. The deal dates back to June 2022, when Re­pare got $125 mil­lion up­front and was el­i­gi­ble for up to $1.2 bil­lion in mile­stones.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.